KOSPIBiotech & Pharma006280

GC Biopharma

₩130,600▼ 3.26%2026-11-18 close
Market Cap
₩1.5T
Turnover
₩2.5B
Volume
20K
Shares out.
11.7M
PER
9.8×
PBR
1.1×
EPS
₩13,698
Dividend Yield
1.12%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩1,500 per share · Prices as of the 2026-11-18 close

01

Report overview

Alyglo growth and one-off gains overlap in Q3

GC Biopharma's Q3 2026 operating profit rose 68.5% year on year, but net income attributable to controlling shareholders also reflected a large Curevo deal payment, so core earnings and one-off items need to be read separately.

  1. 1

    Q3 2026 operating profit was KRW 49.2 billion, up 68.5% year on year, while revenue fell 14.3% year on year to KRW 522.1 billion.

  2. 2

    Q3 net income attributable to controlling shareholders of KRW 222.2 billion includes a large Curevo deal payment and should be separated from core earnings.

  3. 3

    Alyglo sales reached about USD 46 million in Q3 and USD 97 million cumulatively, roughly 65% of the USD 150 million annual target.

  4. 4

    Annual net income attributable to controlling shareholders was a loss for three consecutive years from 2023 to 2025, narrowing to a KRW 4.67 billion net loss in 2025.

02

Business structure

GC Biopharma operates across plasma-derived biologics, vaccines, general pharmaceuticals and trading products.

Its plasma business traces back to 1971, when it set up the first domestic plasma products plant, and a Korean business daily reported in July 2026 that the company has built production and quality control capabilities over more than half a century.

IB Tomato, citing electronic disclosures to the Financial Supervisory Service, reported that plasma product revenue in Q1 2026 was KRW 178.4 billion, or 41% of total revenue, with overseas exports at KRW 88.5 billion and domestic sales at KRW 89.9 billion.

The core of the business is the US immunoglobulin product ALYGLO, which became the first domestically developed plasma product to receive US FDA approval in 2023. A Korean news outlet reported that Alyglo sales in Q3 2026 were about USD 46 million, up 77% year on year.

To secure US plasma supply, the company acquired ABO Holdings, now ABO Plasma, for KRW 138.0 billion and gained seven local plasma collection centers. Vaccines are led by seasonal influenza vaccines, and Q3 2026 results included influenza vaccine sales deferred from Q2.

The hantavirus vaccine Hantabox and a shingles vaccine candidate developed by subsidiary Curevo Vaccine are cited as vaccine capabilities. On March 31, 2026, the company sold its entire stake in GC Wellbeing to GC Holdings, and related revenue has been excluded from consolidation since Q2.

Profit margins by business segment are not separately disclosed, so the profitability gap between plasma products and vaccines cannot be quantified.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩609.5B₩29.2B4.8%
2025Q4₩497.8B₩4.6B0.9%
2026Q1₩435.5B₩11.7B2.7%
2026Q2₩421.2B₩1.7B0.4%
2026Q3₩522.1B₩49.2B9.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩1.7T₩81.3B₩65.5B4.7%4.9%61.2%
2023₩1.6T₩34.4B-₩26.6B2.1%−2.0%71.7%
2024₩1.7T₩32.1B-₩26.3B1.9%−2.1%85.3%
2025₩2T₩69.1B-₩4.7B3.5%−0.4%113.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue went from KRW 1.71 trillion in 2022 to KRW 1.63 trillion in 2023, down 4.9% year on year, then rose to KRW 1.68 trillion in 2024, up 3.3%, and to KRW 1.99 trillion in 2025, up 18.5%. Revenue grew for two consecutive years from 2024 to 2025, and 2025 was the largest year of 2022 to 2025.

Operating profit fell from KRW 81.3 billion in 2022 to KRW 34.4 billion in 2023, down 57.6%, and to KRW 32.1 billion in 2024, down 6.8%, before recovering to KRW 69.1 billion in 2025, up 115.4%.

The operating margin was 4.7% in 2022, 2.1% in 2023, 1.9% in 2024 and 3.5% in 2025, so the 2025 recovery did not return margins to the 2022 level.

Net income attributable to controlling shareholders was KRW 65.5 billion in 2022, turned to a net loss of KRW 26.6 billion in 2023, and remained a loss in 2024 at KRW 26.3 billion and in 2025 at KRW 4.67 billion, which means three consecutive years of losses from 2023 to 2025, with the 2025 loss narrowing sharply.

Net income including non-controlling interests was KRW 69.4 billion in 2022 and then net losses of KRW 19.8 billion, KRW 42.6 billion and KRW 29.7 billion in 2023, 2024 and 2025, a different trajectory from the controlling-shareholder figure.

Operating cash flow was KRW 119.2 billion in 2022, negative at KRW -5.47 billion in 2023 and KRW -53.5 billion in 2024, and turned to KRW 99.5 billion in 2025.

The debt-to-equity ratio rose from 61.2% in 2022 to 113.1% in 2025, with total liabilities of KRW 1.58 trillion and total equity of KRW 1.39 trillion at the end of 2025.

Quarterly results bottomed in Q4 2025, with revenue of KRW 497.8 billion, operating profit of KRW 4.6 billion and a net loss attributable to controlling shareholders of KRW 88.3 billion, before Q1 2026 returned to profit at KRW 20.5 billion.

Operating profit fell to KRW 1.73 billion in Q2 2026 and then rose to KRW 49.2 billion in Q3 2026, up 68.5% year on year, with net income attributable to controlling shareholders of KRW 222.2 billion, and the last four quarters total KRW 156.3 billion.

The company attributed the Q3 operating profit gain to influenza vaccine sales deferred from Q2, Alyglo sales growth and a narrower loss at ABO Plasma.

The jump in controlling-shareholder net income mainly reflected the Curevo deal payment, and Shinyoung Securities analyzed that a KRW 70.0 billion gain on disposal of an associate and KRW 190.0 billion in financial income related to preferred shares flowed in.

05

Industry analysis

Plasma products depend on plasma supply, which makes raw material sourcing the starting point of the business.

According to the Korean Red Cross, domestic self-sufficiency in plasma for pharmaceutical manufacturing was only half last year, and Korea's blood management law prohibits paid blood donation, so supply relies on unpaid donations.

The United States permits compensated plasma donation, which makes raw material procurement comparatively easier. In Korea, immunoglobulin is a essential medicine whose price is set around government-guaranteed production costs, so cost pressure is structurally high.

That is why the company is pairing US sales growth with vertical integration of local plasma collection. Its US pricing is not subject to a sales price cap, which is the premise of this strategy. In vaccines, influenza vaccines follow a seasonal pattern that concentrates sales in Q3.

On the demand side, subcutaneous immunoglobulin is the next growth step, since it offers patient convenience compared with infusions that take an hour or more.

In research, Moderna has begun mRNA-based hantavirus vaccine work with the US Army's infectious disease research institute, which is cited as a sign that the market is expanding.

Because yield largely determines profitability in plasma products, production efficiency from raw plasma to finished product is central to competitiveness.

06

Outlook

The company raised its annual Alyglo revenue target to USD 150 million, and cumulative sales reached USD 97 million through Q3, about 65% of the target. A target of about KRW 400 billion (USD 300 million) in annual revenue from Alyglo alone in 2028 has been presented.

On raw materials, the company has said that once its US plasma collection sites operate normally, it could source about 80% of the plasma needed for Alyglo in-house in 2027.

On the pipeline side, the Fabry disease candidate GC1134A was licensed globally on October 29, 2026, with a total deal value of KRW 317.4 billion, and an upfront payment of KRW 46.8 billion is scheduled to be reflected in Q4 results.

The remaining USD 202.5 million consists of milestones tied to clinical, regulatory and commercial stages and is not confirmed income. The subcutaneous immunoglobulin GC5136 is targeted to enter Phase 3 clinical trials in 2027, with a US FDA license application planned for 2031 after trial completion in 2030.

A new production line costing about KRW 140 billion at the Ochang plant is scheduled for completion by December 31, 2030, and the company expects material revenue contribution after 2030.

Shinyoung Securities estimated 2026 revenue at KRW 1.996 trillion and operating profit at KRW 71.8 billion, and 2027 revenue at KRW 2.173 trillion and operating profit at KRW 118.1 billion, in a report dated November 3, 2026.

The same report said 2026 revenue growth would slow due to the deconsolidation of GC Wellbeing, some product sales shortfalls and a weaker won in the second half.

07

Valuation

PER
9.8×
PBR
1.1×
ROE
11.4%
EPS
₩13,698
BPS
₩126,401
Dividend per share
₩1,500

The share price is trading slightly above the book value attributable to controlling shareholders. With controlling-shareholder equity of KRW 1.22 trillion and a debt-to-equity ratio that rose to 113.1%, the premium over net asset value should be read alongside the capital structure.

Earnings-based multiples are drawn from a period in which the company posted three consecutive annual losses from 2023 to 2025 and then began recovering, so their interpretive range is wide.

The last four quarters' controlling-shareholder net income of KRW 156.3 billion includes the Q3 Curevo deal payment, so multiples on an earnings base excluding one-off items could look different. Dividend yield should be assessed together with the company's capacity to return cash after the loss years.

Among brokerage views, Shinyoung Securities said in a report dated November 3, 2026 that it maintained its investment opinion and a target price of KRW 180,000. The gap between the current share price and that target depends on the assumptions the brokerage has set.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Rapid expansion of Alyglo sales

Alyglo sales reached about USD 46 million in Q3, up 77% year on year, and USD 97 million cumulatively, about 65% of the USD 150 million annual target. A target of about USD 300 million in annual revenue from this single product in 2028 has been presented.

Supporters point to the potential for operating margin improvement as high-margin products gain weight in the mix.

In-house plasma supply and cost structure

ABO Plasma's seven centers have seen higher utilization, easing the fixed-cost burden and narrowing its Q3 loss. The company plans to raise utilization at all centers to 100% by 2028 and to source 80% of Alyglo's plasma internally. Supporters argue that in-house sourcing would reduce exposure to external plasma price swings.

Licensing deals and vaccine portfolio

The Fabry disease candidate GC1134A was licensed globally on October 29, 2026, with an upfront payment of KRW 46.8 billion expected in Q4 results. The total deal value is KRW 317.4 billion, but most of it consists of conditional milestones and is not confirmed income. The hantavirus vaccine Hantabox and the shingles vaccine candidate from Curevo broaden the vaccine portfolio.

09

Bear factors

Revenue decline and seasonal dependence

Q3 revenue of KRW 522.1 billion fell 14.3% year on year, and the operating profit gain was partly helped by influenza vaccine sales deferred from Q2. Influenza vaccine demand tends to soften in the fourth quarter, so quarterly results can swing widely.

Whether profit growth can continue while revenue is shrinking remains a bearish question to watch in coming quarters.

Net income reliant on one-off payments

Q3 net income attributable to controlling shareholders of KRW 222.2 billion was driven largely by the Curevo deal payment. Shinyoung Securities analyzed inflows of a KRW 70.0 billion gain on disposal of an associate and KRW 190.0 billion in preferred-share-related financial income.

Q4 2025 posted a net loss attributable to controlling shareholders of KRW 88.3 billion, which suggests underlying earnings power in quarters without such payments remains thin.

Cost pressure and yield challenges

According to IB Tomato, rising local labor costs, higher blood collection compensation and a strong won have added pressure on the cost ratio. The CEO has emphasized that yield is the key to plasma products, and improving yield was presented as a precondition for expanding the US business.

The company expects material revenue from new production lines only after 2030, leaving this as a medium-term challenge.

10

Risk factors

Plasma supply and regulation

Domestic self-sufficiency in plasma for pharmaceutical manufacturing is about half, and Korea's ban on paid donation limits raw material procurement. Delays in utilization targets at US plasma centers or in FDA approval of follow-on collection sites could disrupt the in-house sourcing plan for Alyglo. US regulatory conditions and plasma price changes are also variables that could affect costs.

Clinical and regulatory timelines

The subcutaneous immunoglobulin GC5136 has a long path to market, with Phase 3 entry targeted for 2027 and an FDA filing for 2031. The remaining USD 202.5 million of the Fabry deal depends on meeting clinical, regulatory and commercial stages. Delays in trial results or regulatory review could push back the medium-term growth scenario.

Currency and cost burden

The US business relies on local selling prices, but rising local labor and blood collection costs push up the cost ratio. Shinyoung Securities expected a weaker won in the second half to slow 2026 revenue growth. A change in currency direction or higher plasma procurement costs could alter the pace of margin improvement.

11

What to watch next

  1. End of December 2026

    Check whether the KRW 46.8 billion Fabry upfront payment is recognized in Q4 and whether additional ABO Plasma collection sites open in the second half. Recognition of the payment would show whether licensing income reaches reported results.

  2. Around February 2027 (Q4 preliminary results)

    Check how seasonal factors and the upfront payment combine in Q4 revenue and operating profit. Also check whether the Q3 influenza vaccine deferral reverses in Q4.

  3. End of March 2027

    In the 2026 annual report, the next periodic filing, confirm annual revenue, operating margin, net income attributable to controlling shareholders and debt ratio from filed figures. The key point is how far the operating margin rises from 3.5% in 2025.

  4. During 2027

    Check whether the Phase 3 investigational new drug application for GC5136 is filed with the FDA and whether the 80% in-house plasma sourcing target is achieved. Both would show progress on the subcutaneous product and cost structure.

12

Overall view

GC Biopharma's filed results show a recovery to KRW 69.1 billion in operating profit in 2025 after three consecutive years of losses from 2023 to 2025.

Q3 2026 produced operating profit of KRW 49.2 billion and net income attributable to controlling shareholders of KRW 222.2 billion, but the net figure includes a large Curevo deal payment, so core earnings and one-off items should be read separately.

On the positive side, cumulative Alyglo sales have reached about 65% of the annual target, and in-house US plasma collection could change the cost structure. On the negative side, Q3 revenue fell 14.3% year on year, and seasonality in influenza vaccines, local cost pressure and yield challenges could weigh on earnings.

The operating margin was 3.5% in 2025 against 4.7% in 2022, so whether revenue recovery is translating into margin recovery is still unproven. The Fabry licensing deal and the SCIG trial are medium-term options, but their confirmed value and commercialization timing remain open.

The next checkpoints are the operating margin in the 2026 annual report and whether the Q4 upfront payment is recognized.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. newsclaim.co.kr
  2. msn.com
  3. 100ssd.co.kr
  4. thebionews.net
  5. getnews.co.kr
  6. newspost.kr
  7. newsvalue.kr
  8. vegannews.co.kr
  9. s-journal.co.kr
  10. dailian.co.kr
  11. hankyung.com
  12. insightkorea.co.kr
  13. ibtomato.com
  14. biztribune.co.kr
  15. m.news.nate.com
  16. dailypharm.com
  17. newsway.co.kr
  18. v.daum.net

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis